ArriVent BioPharma (AVBP) vs MoonLake Immunotherapeutics (MLTX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
MoonLake Immunotherapeutics (MLTX) has outperformed ArriVent BioPharma (AVBP) over the past year, gaining 16.3% versus a loss of 19.7%. MoonLake Immunotherapeutics is the larger company by market cap ($900.4 million vs $823.9 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | AVBP | MLTX |
|---|---|---|
| Share price | $16.71 | $10.58 |
| Market cap | $823.93M | $900.43M |
| 1-day change | -1.07% | -1.76% |
| YTD return | -16.95% | -19.73% |
| 1-year return | -19.74% | +16.26% |
| 5-year return | — | +6.65% |
| EPS (TTM) | $-3.62 | $-3.83 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $35.83 | $23.29 |
| 52-week low | $11.36 | $8.80 |
| Distance from 52-week high | -53.36% | -54.57% |
| Analyst consensus | strong_buy | buy |
| Avg. price target upside | +82.53% | +169.75% |
| Average volume | 908.55K | 1.47M |
| Shares outstanding | 49.31M | 85.11M |
| Employees | 77 | 130 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- MLTX has outperformed AVBP by 36.0 percentage points over the past year.
About ArriVent BioPharma
AVBP stock →ArriVent BioPharma, Inc., a clinical-stage biopharmaceutical company, engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers. The company's lead development candidate is firmonertinib, a tyrosine kinase inhibitor that is being evaluated in multiple clinical trials across a range of epidermal growth factor receptor mutations (EGFRm) in non-small cell lung cancer (NSCLC), including a Phase 3 clinical trial for treatment of patients with advanced or metastatic EGFRm NSCLC with exon 20 insertion mutations, as well as Phase 1b clinical trials to treat NSCLC patients with activating EGFRm, including P-loop and-alpha-c-helix compressing (PACC) mutations, and classical EGFRm NSCLC patients.
Health Care · Biotechnology: Pharmaceutical Preparations · 77 employees
About MoonLake Immunotherapeutics
MLTX stock →MoonLake Immunotherapeutics, a clinical-stage biotechnology company, focuses on developing therapies for inflammatory skin and joint diseases. It develops Sonelokimab, a novel tri-specific IL-17A and IL-17F inhibiting Nanobody for the treatment of inflammatory diseases in dermatology and rheumatology, as well as for hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, palmoplantar pustulosis, and psoriasis.
Health Care · Biotechnology: Pharmaceutical Preparations · 130 employees
AVBP vs MLTX FAQ
Which is bigger, ArriVent BioPharma or MoonLake Immunotherapeutics?
MoonLake Immunotherapeutics (MLTX) is larger, with a market capitalization of $900.43M compared with $823.93M for ArriVent BioPharma (AVBP).
Which stock has performed better over the past year, AVBP or MLTX?
MLTX returned +16.26% over the past 12 months, compared with -19.74% for AVBP (price return, excluding dividends). Past performance does not predict future results.
Are ArriVent BioPharma and MoonLake Immunotherapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.